1 Title: Influence of landscape patterns on the exposure of LASV across diverse regions

2 within the Republic of Guinea

- 3 Stephanie Longet^{*1^}, Cristina Leggio^{*2,6}, Joseph Akoi Bore^{*1,3,4,5}, Tom Tipton¹, Yper Hall²,
- 4 Fara Raymond Koundouno³, Stephanie Key⁶, Hilary Bower⁷, Tapan Bhattacharyya⁶, N'Faly
- 5 Magassouba⁸, Stephan Günther^{9,10} Ana-Maria Henao-Restrapo¹¹, Jeremy S. Rossman^{5,12},
- 6 Mandy Kader Konde⁴, Kimberly Fornace^{6,13}, Miles W. Carroll^{1,2^}
- ⁷ ¹Nuffield Department of Medicine, University of Oxford, Oxford United Kingdom (S.
- 8 Longet, J A. Bore, T. Tipton, Miles W. Carroll)
- ⁹ ²UK Health Security Agency, Porton Down, Salisbury, United Kingdom (C. Leggio, Y. Hall,
- 10 Miles W. Carroll)
- ³Ministry of Health, Conakry, Guinea (J A. Bore, F R. Koundouno)
- ⁴Center for Training and Research on Priority Diseases including Malaria in Guinea,
- 13 Conakry, Guinea (J A. Bore, M K. Konde)
- ⁵University of Kent, School of Biosciences, Canterbury, Kent, United Kingdom (J A. Bore, J
- 15 S. Rossman)
- ⁶Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical
- 17 Medicine, London, United Kingdom (C. Leggio, S. Key, T. Bhattacharyya, K. Fornace)
- ⁷Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical
- 19 Medicine, London, United Kingdom (H. Bower)
- ⁸Projet Laboratoire Fièvres Hémorragiques, Conakry, Guinea (N. Magassouba)
- ⁹Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (S. Günther)
- ¹⁰German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems (S.
- 23 Günther)
- ¹¹World Health Organisation, Geneva, Switzerland (A-M. Henao-Restrapo)
- 25 ¹⁰ RTEs This creptint reports new research that has not been settinged by more seview and should not be used to guide clinical practice.

- ¹³Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow,
- 27 Glasgow, United Kingdom (K. Fornace)

28

- 29 *Contributed equally to first authorship
- 30 ^Corresponding author
- 31

32 Abstract – 150 words

Lassa fever virus (LASV) is the causative agent of Lassa fever, a disease endemic in 33 West Africa. Exploring the relationships between environmental factors and LASV 34 transmission across ecologically diverse regions can provide crucial information for the 35 36 design of appropriate interventions and disease monitoring. We measured LASV-specific IgG seropositivity in 1286 sera collected in Coastal and Forested Guinea. Our results showed that 37 exposure to LASV was heterogenous between the sites. The LASV IgG seropositivity was 38 11.9% (95% CI 9.7-14.5) in Coastal site, while it was 59.6% (95% CI 55.5-63.5) in Forested 39 region. Interestingly, exposure was significantly associated with age, with seropositivity 40 41 increasing with age in the Coastal site. Finally, we also found significant associations between exposure risk to LASV and landscape fragmentation in Coastal and Forested 42 regions. This study may help to define the regions with an increased exposure risk to LASV 43 44 where a close surveillance of LASV circulation is needed.

45

- 46
- 47

49 Introduction

50	Lassa virus (LASV) is an enveloped and negative-sense, single-stranded RNA virus
51	belonging to the Arenaviridae family causing Lassa Fever (LF) in humans (1). Initial clinical
52	presentation is often non-specific and could be indicative of several other febrile illnesses (2).
53	The mortality rate is unclear due to inconsistent reporting practices and lack of diagnostic
54	services in most endemic areas but estimated to 5-20% in hospitalised patients (2) (3).
55	Mastomys natalensis (M. natalensis) is considered as the main natural reservoir, a commensal
56	rodent and agricultural pest which aggregates in human dwellings and surrounding fields (4) .
57	Recent studies have identified additional rodent reservoirs thus revealing the potential for a
58	wider ecological niche for the virus (5). Both zoonotic and non-zoonotic transmission
59	mechanisms have been described (6). Human LASV infections most commonly occur via
60	infected rodent excreta, through contaminated food and inhalation of aerosols from rodent
61	urine or droppings (7) (8). Less commonly, the virus can be transmitted via nosocomial
62	transmission if proper barrier nursing methods are not followed (6) (9).
63	LASV is endemic in West Africa particularly in Nigeria, Sierra Leone, Liberia and
64	Guinea (10) (11). A published estimate on annual cases of LASV infections in West Africa
65	range from 100,000 to 300,000, with 5,000 to10,000 estimated deaths per year and 80%
66	asymptomatic infections. Further epidemiological studies are needed as these figures have
67	been extrapolated from one longitudinal study conducted in Sierra Leone in 1987 (12).
68	Increasing evidence suggests LASV is widespread and substantially under-reported by
69	passive surveillance systems (13). Thus, characterising the distribution and transmission
70	intensity of LASV in endemic areas is essential for the design of effective surveillance and

71 disease control programmes.

72 It was observed that patients, including with mild symptoms, induced LASV-specific antibodies including long-lived IgG (14). Consequently, serological methods can measure 73 long-lived antibody responses and enable estimation of cumulative exposure to pathogens 74 (15). The analysis of age-stratified serological responses is a powerful tool to reconstruct 75 historical patterns of transmission and distribution of previously unreported cases (16) (17). 76 Measurement of LASV-antibody responses has been used to detect circulation of LASV 77 78 across Guinea. Lukashevich et al found 25-55% LASV NP-specific IgG positivity among inhabitants of tropical secondary forest and guinea savannah but only 4-7% positivity among 79 80 inhabitants of mountainous and coastal areas (18). Bausch et al investigated the epidemiology and clinical presentation of the Lassa fever in five Guinean hospitals in 2001. Lassa fever 81 suspected cases were tested using an ELISA platform for antibody detection and the analysis 82 confirmed Lassa fever in 22 (7%) of 311 suspected cases. An additional 43 people (14%) had 83 LASV-specific IgG antibodies, indicating past exposure to LASV (19). Another study aiming 84 to estimate the prevalence of Lassa IgG in human population of rural area of Guinea 85 including Guéckédou, Lola and Yomou (Southern region) indicated 12.9% and 10.0 % IgG 86 positivity in rural and urban areas, respectively (7). While these studies describe the historical 87 circulation of LASV across Guinea, these studies were conducted in the 90's and early 88 2000's. The current burden and the distribution of LASV in Guinea is largely unknown. 89 90 Furthermore, to our knowledge, there are no studies which have estimated transmission 91 intensity from serological data in Guinea and analysed the environmental risk factors. This study aimed to characterise LASV exposure in populations in two ecologically diverse 92 regions of Guinea: the coastal Basse-Guinee region and the forested interior regions of 93 94 Macenta prefecture and Guéckédou. Here, we describe LASV-specific IgG antibody levels within these populations, estimate transmission intensity using age-stratified antibody 95 responses and explore associations with demographic and environmental risk factors. 96

97 Materials and Methods

98 Ethical approval

Basse Guinea site (Coastal site): The study was approved by the London School of
Hygiene and Tropical Medicine Ethics committee (Ethics Ref: 17429) and the Guinean
Ministry of Health (MoH). Macenta site: Ethical approval for research projects in Macenta
and Guéckédou (Forested site) on human volunteers was obtained from the 'Comité national
d'éthique pour la recherche en santé' (CNERS) of Republic of Guinea on the 16th of March
2017 (012/CNERS/17).

105 Study sites

The samples used in this study were initially collected as part of three separate studies focusing on three distinct sites within two geographically diverse regions of Guinea. Basse-Guinee is the coastal region of Guinea, extending for 30-40 miles inland from the Atlantic Ocean to the coastal plains (**Figure 1A**). Macenta prefecture and the city of Guéckédou are located to the south-east of the country, close to the border with Liberia and Sierra Leone, within the forested region of Guinea (**Figure 1A**).

112 Study participants

113 Samples from Basse-Guinee were collected in 2016 as part of a clinical trial evaluating the safety and immunogenicity of the VSV-EBOV Ebola Vaccine in partnership 114 with the Guinean MoH, the World Health Organisation (WHO) and Public Health England 115 (PHE). The samples used for our study were taken prior to vaccination. For this study site, 116 702 samples were randomly selected from the PHE/WHO vaccine trial master database by 117 using the Excel random function and tested for the presence of LASV-specific IgG. 118 Information on volunteers age, sex and village of residence provided at the time of 119 vaccination was used. The selected samples, (participants 6-99 years of age) originated from 120

121 7 prefectures within Basse-Guinee, encompassing 24 subprefectures and 29

122 villages/neighbourhoods.

123 Samples from Macenta region were collected from February to December 2017 as part of a sero-epidemiology study on Ebola virus which included both affected and non-124 affected villages during the 2014-2016 Ebola Virus Diseases (EVD) outbreak (20). In total, 125 126 517 participants (17-90 years of age) living in 44 villages located in 7 subprefectures were enrolled. The volunteers included bush meat hunters, their family members, local health care 127 workers and the general population of the village. Volunteers under 16 years of age, pregnant 128 women, travellers or visitors, and people suffering from chronic disease were excluded from 129 the original study. In total, 516 samples from the Macenta cohort were analysed. For the 130 purpose of the analysis, 68 samples from Guéckédou city, collected in 2018 in the context of 131 a longitudinal study of EVD survivors, were included in the Macenta population. Both 132 Guéckédou city and Macenta prefecture are forested regions. All samples were stored at -133 80°C in a temperature monitored unit within the PHE Porton Down UK laboratories. 134

135 Consent forms stating the study aims and their rights as volunteers were signed prior to136 sample collection for each individual study.

137 Blood sample collection and processing

A volume (5-20ml) of human peripheral blood was collected into non-anticoagulant BD Vacutainer[®] blood collection tubes from participants. Blood clotted within two hours and transported to the laboratory in a cool box at 4°C. Samples were centrifuged at 2,000 x g for 10 minutes at room temperature and serum aliquoted into 2 ml microtube RT-PCR tubes (Starsted, REF 72.694.406) in an air purifying class II microbiological safety cabinet (Envair Ltd, England). Aliquots of sera were shipped on dry ice at -20°C and processed at PHE Porton Down laboratories (England).

145 Samples analysis by LASV-specific ELISA

146	To measure anti-LASV IgG specific antibodies in sera, the patented BLACKBOX®
147	LASV IgG kit from Bernhard Nocht Institute for Tropical Medicine (BNITM) in Germany
148	(ELG.004) used for qualitative serological detection of acute or past LASV infection (21)
149	(22). The kit was used as per the manufacturer's instructions. Each sample was run as single
150	replicate. All reagents were provided by BNITM. Positive and negative controls were
151	provided with the kit. Blank and background wells were added to monitor non-specific
152	bindings of proteins to reagent contaminants or to the ELISA plate surface. Briefly, initial
153	plate washing was performed using pre-diluted wash buffer. Then, 25uL of diluted
154	biotinylated recombinant LASV antigen (nucleoprotein) were transferred onto the ELISA
155	plate and 25uL of diluted control or patient sample added prior to plate incubation for 24h at
156	4°C in a humid chamber. After a wash step, 50uL of diluted streptavidin/Horseradish
157	Peroxidase (HRP) were added and plate incubated for 1h at 4°C. Another wash step was
158	performed, 100uL/well of 3,3',5,5'-Tetramethylbenzidine (TMB) peroxidase substrate were
159	added and plate incubated for 10min at room temperature in the dark. Finally, 100uL/well of
160	Stop solution (1M H ₂ SO ₄) were added and optical density (OD) readings (450-620nm)
161	obtained by using SpectraMax plate reader (software SoftMaxPro v9). As recommended in
162	the BLACKBOX® LASV IgG ELISA manual, results were interpreted as valid if the
163	following criteria were met: OD450-OD620 of negative control < 0.10 and OD450-OD620 of
164	positive control > 1.00. Average absolute OD450-OD620 absorbance value for negative
165	control samples $(OD_{Neg,AV})$ was used to calculate the assay cut off OD_{CO} according to the
166	following formula:

167 $OD_{Neg,AV} + 0.150 = OD_{CO}$

168 Index Values (IV) for the tested samples were calculated as follows:

- 169 $IV_{sample} = OD450-OD620 \text{ (sample)} / OD_{CO}$
- 170 Results classification for index values was carried out as follows:
- 171 $IV_{sample} \ge 1.00 = POSITIVE$
- 172 $0.90 < IV_{sample} < 1.00 = EQUIVOCAL$
- 173 $IV_{sample} \leq 0.90 = \text{NEGATIVE}$
- 174 Environmental and spatial covariates

To assess the impact of land cover and other environmental covariates on LASV exposure, we assembled a dataset of remote-sensing derived land cover maps from 2017 at 100m resolution (23). We reclassified land cover into the following categories: closed forest (canopy cover >70%), open forest (canopy cover 15-70%), shrubs, herbaceous vegetation (plants without persistent stems and canopy cover <10%) and urban/built up areas. We additionally extracted data on the percentage canopy cover for all sites. Population density was obtained from village level population estimates of all sampled areas.

As sampled villages were only geolocated to centroids, we extracted environmental 182 data within buffer radii of 500m, 1km, 2km, 5km and 10km from the village centroid to 183 represent the possible distributions of the village and lands used (24). For all buffer radii, we 184 extracted the proportions of different land cover types and the mean canopy cover. To 185 evaluate the importance of landscape configuration, we additionally extracted metrics on 186 fragmentation, including perimeter area ratio, shape index (patch perimeter divided by the 187 minimum possible patch perimeter) and fractal dimension index (an index of shape 188 complexity) (25). In ecology, fragmentation is defined as the breaking up of habitat and it is 189 often used as a measurable index, usually related to human activity, which produces loss or 190 191 reduction in habitat size or increased isolation of habitats.

192 Statistical analyses

To characterise transmission intensity in both sites, we first graphed both continuous antibody responses and age-specific estimates of seropositivity. Reversible catalytic models were fit to age sero-prevalence data using maximum likelihood methods (*15*). We used profile likelihood plots to explore possible historical changes in transmission intensity, with final models selected using likelihood ratio tests (*26*). Final models were used to estimate seroconversion rates (SCR).

199 We additionally assessed whether fine-scale patterns of serological exposure were associated with landscape characteristics. As environmental variables can be associated with 200 201 risk at different spatial scales, we used a data-driven approach to identify environmental risk 202 factors (27). First, mixed-effects logistic regression models were run for each environmental 203 variable at each spatial scale (126 in total) to identify factors associated with LASV seropositivity. Models were run separately for both sites, with the primary outcome as the 204 205 binary classification for individual level seropositivity. Models were fit with village as a random effect to account for observations within villages lacking independence. We first 206 assessed associations with key demographic factors, including gender, continuous age and 207 age category. For the Macenta/Guéckédou (forested region) model, only environmental 208 209 predictors were included as demographic factors (age, gender) were not associated with 210 exposure risks. For the coastal site, age category was included in all models in addition to environmental predictors. When assessing for inclusion in the multivariate analysis, 211 univariate results were considered significant at p < 0.2 to avoid exclusion of variables that 212 213 alone lack significance but contribute in presence of other variables. Highly correlated variables (Pearson's correlation coefficient > 0.75) were removed. Where environmental 214 covariates appeared significantly associated with the outcome of interest across multiple 215 buffer radii, inclusion in the final model was based on Akaike's Information Criteria (AIC). 216

Final multivariate models were fit in a forward stepwise manner using AIC, with variables considered significant at p < 0.05.

219 **Results**

Within this study, we assessed LASV IgG seropositivity in 1286 individuals using
serum samples collected from the period of 2016 to 2018 in Guinea. In the Coastal site, 702
samples were analysed from 7 prefectures, encompassing 24 subprefectures and 29
villages/neighbourhoods (Figure 1A, Table 1, Appendix Table 1). In the Forested site, 516
samples were analysed from Macenta prefecture and 68 from Guéckédou city. The Macenta
samples originated from 7 subprefectures encompassing 44 villages (Figure 1A, Table 1,

226 Appendix Table 2).

Coastal site		Forested Region	
N	702	Ν	584
		Macenta	516
		Guéckédou	68
Female	243 (34.6%)	Female	262 (44.9%)
Male	459 (65.4%)	Male	322 (51.1%)
Age range (years)	6-99	Age range (years)	17-90
Mean age (years)	32.3	Mean age (years)	38.8
Sampling dates	2016	Sampling dates	2017-2018

Table 1: Study participants of coastal and forested regions.

228 We observed that exposure to LASV was highly heterogenous both between (Figure 1A) and

within (Figure 1B) each study site. The LASV IgG seropositivity was 11.9% (95% CI 9.7-

- 14.5) in the Coastal site (Figure 1B, Appendix Table 1), while it was 59.6% (95% CI 55.5-
- 63.5) in the Forested site (**Figure 1B**, **Appendix Table 2**).







242



243



Demographic characteristics of exposed individuals varied by study site. In the 247 Coastal site, seropositivity in females was 9.0% (95% CI 5.8-13.1) and in males was 13.5% 248 (95% CI 11.0-17.0). For the Forested site, seropositivity in females was 61.8% (95% CI 56.0-249 67.7) and in males was 58% (95% CI 52.5-63.3). Gender was not significantly associated 250 251 with seropositivity in either site.

Age patterns of seropositivity differed markedly between sites. In the Coastal site, 252 exposure was strongly associated with age, with seropositivity increasing with age (Figure 253

2A). However, no correlation was found between the quantitative antibody responses 254 expressed by Index Value and age among seropositive individuals (Appendix Figure 1). 255 Within this population, reversible catalytic models estimated the force of infection 256 (Seroconversion rate = SCR) as 0.0041 (95% CI: 0.0033 - 0.0050). No changes in historical 257 transmission intensity were detected (p = 0.328). In contrast, within the Forested site, no clear 258 age patterns were identified and neither continuous nor categorical age were associated with 259 260 individual seropositivity (Figure 2B). Although age ranges for included individuals were different between both sites (Table 1), substantial differences in exposure risks were detected 261 262 in similar age groups between sites. For example, individuals aged 17-20 had an estimated seropositivity of 5.4% (95% CI: 1.5-13.3%) in the Coastal site compared to 50.0% in the 263 Forested site (95% CI: 37.2 - 62.8%). The high proportions of seropositivity in the youngest 264 age groups and lack of association with age precluded fitting reversible catalytic models for 265 the Forested region. 266



Figure 2. Proportion seropositive with 95% Confidence intervals by age decile for Coastal
site (A) and Forested site (B), blue line is modelled SCR curve.

Despite clear differences in transmission between sites, strong associations between 271 exposure and environmental factors were identified for both sites. The land cover classes for 272 both sites are shown in Figure 3A. As characterised by perimeter area ratios, fragmentation 273 was strongly positively associated with exposure risk for both sites (Figure 3B and C, 274 Appendix Tables 3 and 4). In the Coastal site, the proportion of open forests and 275 fragmentation of built up areas increased odds of exposure. Other land cover factors, such as 276 277 closed forests and vegetation fragmentation, were not significantly associated with exposure risks but improved overall model fit (Figure 3B, Appendix Table 3). Within the Forested 278 279 site, increased fragmentation of both open and closed forests was positively associated with risk, while fragmented vegetation was protective (Figure 3C, Appendix Table 4). Across 280 both sites, significant variables were identified at different spatial scales, consistent with 281 other studies of environmental risk factors for zoonotic diseases (28). 282





291



Figure 3: A) Land cover classes for the Coastal and Forested sites. B and C) Associations
between exposure risk and environmental factors in the Coastal (B) and Forested sites (C).
OR: Odd ratios. CI: Confidence intervals.

301 Discussion

Despite the growing interest in Lassa fever, there is limited up-to-date information 302 regarding the seropositivity of LASV in West Africa. To our knowledge, this study is the first 303 304 one to estimate transmission intensity from serological data in Guinea and analyse the environmental risk factors. We found that LASV NP-specific IgG seropositivity differed 305 between our study sites: Coastal and Forested regions. In 1993, Lukashevich and colleagues 306 had also found a high LASV NP-specific IgG positivity among inhabitants of tropical 307 secondary forest (areas near Guéckédou, Yomou, and Lola) and guinea savannah (Faranah 308 and Kindia areas) (25-55%) and a lower positivity among inhabitants of mountainous (Pita, 309 Labe, and Mali) and coastal areas (Boffa, Boké) (4-7%) (18). In our study, we found that 310 gender was not significantly associated with seropositivity in either site, which is in line with 311 312 other studies conducted both in Guinea and Sierra Leone (18) (12). Interestingly, our findings showed a significant increase in LASV IgG seropositivity with age in the Coastal site but not 313 314 in the Forested site. Although in the above-mentioned study, Lukashevich and colleagues did not detect any correlation between antibody prevalence and age in any studied regions (18), 315

differences in age patterns of seropositivity between regions were observed in other studies in 316 West Africa. A study conducted in Forested Guinea in the year 2000, found individuals under 317 10 and between 20 and 29 years of age to have the highest LASV IgG prevalence (7). A 318 study conducted in Sierra Leone, found antibody prevalence to increase with age, reaching a 319 peak at 20-50 years of age and decreasing thereafter (12). A similar trend was reported in 320 another pilot study conducted in 2015 in Nigeria (29). Age, often associated with occupation 321 322 or daily activities, may play a role on exposure but our results in the forested region and others studies suggest that in some regions, other factors such as environmental features may 323 324 have a bigger impact on exposure risk. It is also possible that more localised exposure within the household plays a role for viral transmission. Finally, we found an association between 325 landscape patterns and exposure risk for both study sites. Associations between landscape 326 327 fragmentation and exposure risk to zoonotic diseases have been observed for other zoonotic diseases such as malaria (28) (30) and Ebola virus (31). In our study, the fragmentation of 328 forests and their proportion appear to have an impact on exposure risk but their exact role in 329 the complex dynamics of LASV circulation remains to be determined. 330

The murine population is another variable involved in the distribution of LASV. In 331 one study looking at LASV-specific IgG prevalence in the reservoir host *M. natalensis* in 332 Guinea, the authors found that 0% of the M. natalensis were infected with Lassa virus in the 333 334 low seroprevalence area (the coastal region) while 5.4%-32.1 % of sampled mice were infected with the virus in the high seroprevalence region (forested guinea) (10). Another 335 study sampled a total of 1616 small rodents (956 Mastomys sp.) captured in 444 households 336 in the savanna, mixed savanna-forest and forest region of Guinea were studied for LASV-337 specific antibody and antigen detection. The authors found that the proportion of LASV 338 infected rodents per region ranged from 0% - 9%. It was higher in the savannah and forested 339 areas. Interestingly, they observed that the proportion of infected animals in each village was 340

highly variable amongst neighboring villages, identifying 'hot spots' of LASV infected mice
clustering within few homes, thus adding a further element that could drive the highly
heterogeneous distribution of LASV (*32*). Even though the distribution of *M. natalensis* is an
important factor, its presence may not be sufficient to explain the IgG seropositivity in
humans (*33*) (*10*), as additional rodent reservoirs have been identified revealing the potential
for a wider ecological niche for LASV (*5*).

Finally, some limitations of our study can be highlighted. The type of ELISA used to 347 assess LASV seropositivity may impact on the results. Even though the BLACKBOX IgG 348 ELISA was shown to be sensitive and very specific (90% and 99%) when compared to the 349 immunofluorescence assay (21), it was not tested against other arenaviruses due to lack of 350 suitable serum panels. Consequently, we cannot fully exclude the potential circulation of 351 related, or perhaps yet undescribed arenaviruses, in specific regions (34) and a partial cross-352 reactivity of IgG antibodies against other arenaviruses. In addition, as the samples were 353 354 collected as part of a vaccine evaluation and a sero-epidemiology study on Ebola virus, the sampling procedure was not standardised between the studies. It would have been useful to 355 have additional information on individual's LASV exposure risks i.e. occupation, relevant 356 357 medical history, hunting/foraging habits, location of previous residence, methods for food storage and rodents trapping around the house. It would be useful to know the number of 358 359 people in the household, the quality of the building, as well as presence of rodent burrows in or around the house. Finally, this study measured only IgG antibodies in sera collected at one 360 timepoint. As such, our data does not allow us to capture the potential effect of changes in 361 seasonal rodent activity or vegetation patterns surrounding the villages. Also, since people 362 tend to move frequently across wide regions, either to find work during harvest season or to 363 hunt (35) and some may have moved away from Ebola virus disease hotspots during the 364

2013-2016 outbreak, they may have been exposed to LASV in a different location from theone in which they resided at the time of sampling.

367 Similar to other endemic tropical diseases, LASV dynamics result from complex interactions between several human and environmental factors. Our study compared the 368 LASV-specific IgG seropositivity in Coastal and Forested regions in Guinea and for the first 369 370 time described in detail association between exposure to LASV and landscape patterns. Enhanced knowledge of regions with an a potentially increased exposure risk to LASV can 371 help to improve the epidemiological surveillance, devise one health interventions and 372 highlight potential trial sites to assess new LASV vaccines and therapeutics. 373 Acknowledgments 374 375 This work was funded by the US Food & Drug Administration (HHSF223201510104C) and the CGIAR Research Program on Agriculture for Nutrition and Health (A4NH). SG was 376

supported by grants GU883/5-1 and GU883/5-2 from the German Research Foundation (DFG).
KMF is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and
the Royal Society (Grant no. 221963/Z/20/Z).

380 **References**

1. Hensley, L.E.; Smith, M.A.; Geisbert, J.B.; Fritz, E.A.; Daddario-DiCaprio, K.M.;

382 Larsen, T.; et al. Pathogenesis of Lassa fever in cynomolgus macaques. Virol J 2011,
383 8, 205.

- Richmond, J.K.; Baglole, D.J. Lassa fever: epidemiology, clinical features, and social
 consequences. BMJ 2003, 327, 1271-1275.
- 386 3. McCormick, J.B.; Walker, D.H.; King, I.J.; Webb, P.A.; Elliott, L.H.; Whitfield, S.G.;
- 387et al. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am J Trop Med
- 388 Hyg 1986, 35, 401-407.

389	4.	Monath, T.P.; Newhouse, V.F.; Kemp, G.E.; Setzer, H.W.; Cacciapuoti, A. Lassa
390		virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone.
391		Science 1974, 185, 263-265.
392	5.	Olayemi, A.; Oyeyiola, A.; Obadare, A.; Igbokwe, J.; Adesina, A.S.; Onwe, F.; et al.
393		Widespread arenavirus occurrence and seroprevalence in small mammals, Nigeria.
394		Parasit Vectors 2018, 11, 416.
395	6.	Fisher-Hoch, S.P.; Tomori, O.; Nasidi, A.; Perez-Oronoz, G.I.; Fakile, Y.; Hutwagner,
396		L.; et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor
397		medical practice. BMJ 1995, 311, 857-859.
398	7.	Kerneis, S.; Koivogui, L.; Magassouba, N.; Koulemou, K.; Lewis, R.; Aplogan, A.; et
399		al. Prevalence and risk factors of Lassa seropositivity in inhabitants of the forest
400		region of Guinea: a cross-sectional study. PLoS Negl Trop Dis 2009, 3, e548.
401	8.	Stephenson, E.H.; Larson, E.W.; Dominik, J.W. Effect of environmental factors on
402		aerosol-induced Lassa virus infection. J Med Virol 1984, 14, 295-303.
403	9.	Ajayi, N.A.; Nwigwe, C.G.; Azuogu, B.N.; Onyire, B.N.; Nwonwu, E.U.;
404		Ogbonnaya, L.U.; et al. Containing a Lassa fever epidemic in a resource-limited
405		setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-
406		March 2012). Int J Infect Dis 2013, 17, e1011-1016.
407	10.	Lecompte, E.; Fichet-Calvet, E.; Daffis, S.; Koulemou, K.; Sylla, O.; Kourouma, F.;
408		et al. Mastomys natalensis and Lassa fever, West Africa. Emerg Infect Dis 2006, 12,
409		1971-1974.
410	11.	Ogbu, O.; Ajuluchukwu, E.; Uneke, C.J. Lassa fever in West African sub-region: an
411		overview. J Vector Borne Dis 2007, 44, 1-11.

- 412 12. McCormick, J.B.; Webb, P.A.; Krebs, J.W.; Johnson, K.M.; Smith, E.S. A
- prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 1987,
 155, 437-444.
- 415 13. Gibb, R.; Moses, L.M.; Redding, D.W.; Jones, K.E. Understanding the cryptic nature
 416 of Lassa fever in West Africa. Pathog Glob Health 2017, 111, 276-288.
- 417 14. Bond, N.; Schieffelin, J.S.; Moses, L.M.; Bennett, A.J.; Bausch, D.G. A historical
- 418 look at the first reported cases of Lassa fever: IgG antibodies 40 years after acute

419 infection. Am J Trop Med Hyg 2013, 88, 241-244.

- 420 15. Drakeley, C.J.; Corran, P.H.; Coleman, P.G.; Tongren, J.E.; McDonald, S.L.;
- 421 Carneiro, I.; et al. Estimating medium- and long-term trends in malaria transmission
- 422 by using serological markers of malaria exposure. Proc Natl Acad Sci U S A 2005,

423 102, 5108-5113.

- 424 16. Greenhouse, B.; Daily, J.; Guinovart, C.; Goncalves, B.; Beeson, J.; Bell, D.; et al.
- 425 Priority use cases for antibody-detecting assays of recent malaria exposure as tools to
 426 achieve and sustain malaria elimination. Gates Open Res 2019, 3, 131.
- 427 17. Arnold, B.F.; Scobie, H.M.; Priest, J.W.; Lammie, P.J. Integrated Serologic
- 428 Surveillance of Population Immunity and Disease Transmission. Emerg Infect Dis
 429 2018, 24, 1188-1194.
- Lukashevich, I.S.; Clegg, J.C.; Sidibe, K. Lassa virus activity in Guinea: distribution
 of human antiviral antibody defined using enzyme-linked immunosorbent assay with
 recombinant antigen. J Med Virol 1993, 40, 210-217.
- Bausch, D.G.; Demby, A.H.; Coulibaly, M.; Kanu, J.; Goba, A.; Bah, A.; et al. Lassa
 fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector
 Borne Zoonotic Dis 2001, 1, 269-281.

436	20	Thom $\mathbf{R} \cdot \mathbf{Tipton}$	T · Strecker	$T \cdot H_{2}$	Y · Akoi Bore	I · Maes P · d	et al
430	<i>2</i> 0.	110111, K., 1101011,	I., SUECKEI,	1., 11all,	I., AKUI DUIC,	J., WIGES, F., 9	5t al.

- 437 Longitudinal antibody and T cell responses in Ebola virus disease survivors and
- 438 contacts: an observational cohort study. Lancet Infect Dis 2021, 21, 507-516.
- 439 21. Gabriel, M.; Adomeh, D.I.; Ehimuan, J.; Oyakhilome, J.; Omomoh, E.O.; Ighodalo,
- 440 Y.; et al. Development and evaluation of antibody-capture immunoassays for
- detection of Lassa virus nucleoprotein-specific immunoglobulin M and G. PLoS Negl
- 442 Trop Dis 2018, 12, e0006361.
- 443 22. Schmitz, H.; Gabriel, M.; Emmerich, P. Specific detection of antibodies to different
- 444 flaviviruses using a new immune complex ELISA. Med Microbiol Immunol 2011,
- 445 200, 233-239.
- Buchhorn, M.; Smets, B.; Bertels, L.; De Roo, B.; Lesiv, M.; Tsendbazar, N.-E.; et al.
 Copernicus Global Land Service: Land Cover 100m: collection 3: epoch 2019: Globe.
- 448 Zenodo 2020.
- 449 24. Brock, P.M.; Fornace, K.M.; Grigg, M.J.; Anstey, N.M.; William, T.; Cox, J.; et al.
- 450 Predictive analysis across spatial scales links zoonotic malaria to deforestation. Proc
 451 Biol Sci 2019, 286, 20182351.
- 452 25. McGarigal, K.; Cushman, S.; Catherine Neel, M.; E., E. Spatial Pattern Analysis
 453 Program for Categorical Maps. Available online:
- 454 www.umass.edu/landeco/research/fragstats/fragstats.html
- 455 26. Stewart, L.; Gosling, R.; Griffin, J.; Gesase, S.; Campo, J.; Hashim, R.; et al. Rapid
- 456 assessment of malaria transmission using age-specific sero-conversion rates. PLoS
- 457 One 2009, 4, e6083.
- 458 27. Fornace, K.M.; Brock, P.M.; Abidin, T.R.; Grignard, L.; Herman, L.S.; Chua, T.H.; et
- 459 al. Environmental risk factors and exposure to the zoonotic malaria parasite

460		Plasmodium knowlesi across northern Sabah, Malaysia: a population-based cross-
461		sectional survey. Lancet Planet Health 2019, 3, e179-e186.
462	28.	Stefani, A.; Dusfour, I.; Correa, A.P.; Cruz, M.C.; Dessay, N.; Galardo, A.K.; et al.
463		Land cover, land use and malaria in the Amazon: a systematic literature review of
464		studies using remotely sensed data. Malar J 2013, 12, 192.
465	29.	Tobin, E.; Asogun, D.; Akpede, N.; Adomeh, D.; Odia, I.; Gunther, S. Lassa fever in
466		Nigeria: Insights into seroprevalence and risk factors in rural Edo State: A pilot study.
467		J Med Trop 2015, 17, 51-55.
468	30.	Fornace, K.M.; Abidin, T.R.; Alexander, N.; Brock, P.; Grigg, M.J.; Murphy, A.; et
469		al. Association between Landscape Factors and Spatial Patterns of Plasmodium
470		knowlesi Infections in Sabah, Malaysia. Emerg Infect Dis 2016, 22, 201-208.
471	31.	Olivero, J.; Fa, J.E.; Real, R.; Marquez, A.L.; Farfan, M.A.; Vargas, J.M.; et al.
472		Recent loss of closed forests is associated with Ebola virus disease outbreaks. Sci Rep
473		2017, 7, 14291.
474	32.	Demby, A.H.; Inapogui, A.; Kargbo, K.; Koninga, J.; Kourouma, K.; Kanu, J.; et al.
475		Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in
476		small mammals. Vector Borne Zoonotic Dis 2001, 1, 283-297.
477	33.	Marien, J.; Kourouma, F.; Magassouba, N.; Leirs, H.; Fichet-Calvet, E. Movement
478		Patterns of Small Rodents in Lassa Fever-Endemic Villages in Guinea. Ecohealth
479		2018, 15, 348-359.
480	34.	Coulibaly-N'Golo, D.; Allali, B.; Kouassi, S.K.; Fichet-Calvet, E.; Becker-Ziaja, B.;
481		Rieger, T.; et al. Novel arenavirus sequences in Hylomyscus sp. and Mus (Nannomys)
482		setulosus from Cote d'Ivoire: implications for evolution of arenaviruses in Africa.
102		PLoS One 2011, 6, e20893.

484	35.	Mari Saez, A.; Cherif Haidara, M.; Camara, A.; Kourouma, F.; Sage, M.;
485		Magassouba, N.; et al. Rodent control to fight Lassa fever: Evaluation and lessons
486		learned from a 4-year study in Upper Guinea. PLoS Negl Trop Dis 2018, 12,
487		e0006829.
488		
489	A	Address for correspondence: Prof Miles W. Carroll & Dr Stephanie Longet, Nuffield
490	Γ	Department of Medicine, Wellcome Centre for Human Genetics, University of Oxford,
491	C	Oxford, OX3 7BN, United Kingdom. Emails and phone numbers:
492	<u>n</u>	niles.carroll@ndm.ox.ac.uk (+447920232324) and
493	<u>S</u>	tephanie.longet@well.ox.ac.uk (+441865617892).
494		